Navigation Links
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
Date:3/3/2017

CONCORD, Mass., March 3, 2017 /PRNewswire/ -- Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary antibody delivery technology with recombinant human acid alpha-glucosidase (rhGAA) to improve the delivery of rhGAA into affected tissues of patients with Pompe disease (Glycogen Storage Disease, Type II; GSDII).  Pompe disease is caused by a deficiency of the lysosomal enzyme, GAA, that leads to accumulation of glycogen in multiple tissues, with cardiac and skeletal muscles being the most severely affected.  Glycogen, a complex sugar, is known to accumulate in both the lysosomes and cytoplasm of late-onset Pompe disease patients. However, the currently approved enzyme-replacement therapy is limited to the lysosome for therapeutic activity.

In a study recently published by Sun et al, Duke University, Division of Medical Genetics (J Mol Med, 2 Feb, 2017), Valerion's proprietary antibody-mediated enzyme replacement therapy [VAL-1221 (humanized 3E10Fab-GAA)] demonstrated efficacy in both cultured Pompe patient fibroblasts and in Pompe (GAA-deficient) mice. Importantly, not only did VAL-1221 reduce lysosomal glycogen accumulation as effectively as rhGAA (current enzyme replacement therapy or ERT) but it was also demonstrated to penetrate living cells independent of the mannose-6-phopsphate receptor (M6PR), the mechanism of cell entry associated with current ERT which directs enzyme to the lysosome. These results suggest that VAL-1221 has potential benefit over current ERT by clearing both lysosomal and cytoplasmic glycogen.  

Valerion is initiating a clinical trial in both the US (Duke University Medical Center) and the UK (The National Hospital for Neurology and Neurosurgery, London) next month to evaluate this novel therapy in patients with late-onset Pompe disease.

"We believe our findings are a game-changer in the treatment of Pompe disease," said Deborah Ramsdell, Valerion's Chief Executive Officer. "We are excited about the potential to help patients who are looking for alternatives to the current approved therapy."

This randomized, parallel active control, single and repeat dose, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of VAL-1221 in ambulatory and ventilator-free patients with late-onset Pompe Disease.  Top line results are expected later this year.

"The approach is different from other ERT approaches as this has the ability to act on glycogen in the cytoplasm. This remains a challenge in the field of Pompe disease," said Dr. Priya Kishnani, Principal Investigator at Duke University Medical Center. "Glycogen that is leached out (either due to shearing effect or rupture of lysosomes) into cytoplasm needs to be cleared.  The collaboration with Valerion is an important one as it allows us to look at whether VAL-1221 has this additional benefit."

About Valerion Therapeutics

Valerion Therapeutics (www.valerion.com) is a biotechnology company focused on developing therapies for orphan genetic diseases utilizing a proprietary antibody-mediated delivery platform to target specific tissues. 

This platform is capable of enhanced intracellular delivery of a variety of active therapeutic molecules via a well-known and broadly studied transport mechanism that is present in muscles and neurons.  Pipeline candidates include therapies aimed at addressing orphan genetic disorders with limited or no current therapies.  Valerion Therapeutics is part of the Alopexx Enterprises portfolio of companies (www.alopexx.com).

Media Contact  
Deborah Ramsdell  
Deb.ramsdell@alopexx.com  
781-775-7688

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valerion-therapeutics-demonstrates-a-new-mechanism-for-treating-pompe-disease-300417564.html


'/>"/>
SOURCE Valerion Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
2. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
3. Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies - Research and Markets
4. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets
5. United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference
6. MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer
7. Dermatology Therapeutics Drug Development Pipeline Review, 2016: Approximately One-Third of the US Population Suffers from at Least One Active Skin Condition - Research and Markets
8. Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast
9. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pharmaceuticals
10. Global Peripheral Arterial Disease (PAD) Therapeutics - Pharmaceuticals
11. Entest BioMedical Inc.s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):